Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070452 | 1.00 | ALOX5 (0.50) | ALOX5CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4251872 | 0.79 | ALOX5 (0.54) | ALOX5CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10371256 | 0.77 | ALOX5 (0.48) | ALOX5CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL29478377 | 0.76 | CYP2A6 (0.51) | CYP2A6HDAC6POLBCMA1TAAR1 | |
| SCHEMBL29478399 | 0.76 | CYP2A6 (0.51) | CYP2A6HDAC6POLBCMA1TAAR1 | |
| SCHEMBL2030632 | 0.76 | CYP2A6 (0.51) | CYP2A6HDAC6POLBCMA1TAAR1 | |
| SCHEMBL2030630 | 0.76 | CYP2A6 (0.51) | CYP2A6HDAC6POLBCMA1TAAR1 | |
| SCHEMBL2032877 | 0.76 | CYP2A6 (0.51) | CYP2A6HDAC6POLBCMA1TAAR1 | |
| SCHEMBL8126573 | 0.76 | ALOX5 (0.57) | ALOX5CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9764840 | 0.75 | ALOX5 (0.60) | ALOX5CYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013091903-A1 | ANTI-CRAC CHANNEL ANTIBODIES | NOVO NORDISK A/S (DK) | 2013-06-27 | — | — | WO | disclosed |
| US-7868135-B2 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | BIOWEST THERAPEUTICS INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| EP-2147925-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2010-01-27 | — | — | EP | disclosed |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| WO-2008080223-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-10 | — | — | WO | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
| EP-1656390-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2006-05-17 | — | — | EP | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
| WO-2005000878-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | ALOX5 2621/4885CYP1A2 3094/4885CYP2D6 2435/4885 |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | ALOX5 462/4885CYP1A2 4441/4885CYP2D6 3766/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | ALOX5 1606/4885CYP1A2 4344/4885CYP2D6 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.